Treating HepG2 cells with desferrioxamine, an iron chelator that stabilizes HIF-1α, increased hepatoma migration threefold, demonstrating a role for HIF-1α in hepatoma migration independent of HCV infection. This evidence concerns the gene HIF1A and hepatocellular carcinoma.